OddEyeCircle
2021-12-17
Please let me know if
2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":699022049,"tweetId":"699022049","gmtCreate":1639725945378,"gmtModify":1639725945737,"author":{"id":3582065904370135,"idStr":"3582065904370135","authorId":3582065904370135,"authorIdStr":"3582065904370135","name":"OddEyeCircle","avatar":"https://static.tigerbbs.com/bd89742cea79ac97ec7da1a7bdbc2a14","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":38,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Please let me know if</p></body></html>","htmlText":"<html><head></head><body><p>Please let me know if</p></body></html>","text":"Please let me know if","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/699022049","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","kind":"news","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p>\n<p>Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p>\n<p>Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p>\n<p>IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p>\n<p>The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p>\n<p>Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p>\n<p>Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p>\n<p>Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p>\n<p>Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p>\n<p>Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p>\n<p>Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p>\n<p>Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 15:00 GMT+8 <a href=https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BNOX":"Bionomics Limited"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1},"isVote":1,"tweetType":1,"viewCount":412,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/699022049"}
精彩评论